What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. (Q30249635)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

1 reference

3 references

21 October 2020

17 January 2024

What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

4 references

20 August 2019

17 September 2019

7 November 2019

21 October 2020

physiological phenomenon

1 reference

bacterial drug resistance

20 August 2019

heterocyclic compound

1 reference

17 September 2019

1 reference

7 November 2019

1 reference

21 October 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Hongxin Zhao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Vladyslav Nikolayevskyy

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

R J Harris

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

H-A Hatherell

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

D Obach

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

N Tsuchiya

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

K Kranzer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

J Kim

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

M C Lipman

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

I Abubakar

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

language of work or name

English

0 references

publication date

13 June 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 October 2016

2 references

21 October 2020

17 January 2024

8 references

23 March 2019

22 June 2019

20 August 2019

17 September 2019

7 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

21 October 2020

17 January 2024

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

940-949

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

13 March 2020

copyright license

7 references

23 March 2019

22 June 2019

20 August 2019

17 September 2019

7 November 2019

21 October 2020

17 January 2024

0 references

Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Treatment of latent tuberculosis infection: a network meta-analysis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Prospective randomized trial of six-month versus nine-month therapy for intestinal tuberculosis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

ACONCURRENT COMPARISON OF INTERMITTENT (TWICE-WEEKLY) ISONIAZID PLUS STREPTOMYCIN AND DAILY ISONIAZID PLUS PAS IN THE DOMICILIARY TREATMENT OF PULMONARY TUBERCULOSIS; TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Response of patients infected with isoniazid-resistant tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Clinical evaluation of ethambutol in pulmonary tuberculosis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Controlled clinical trials with Isoxyl

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

[Intermittent treatment of "intractable chronic tuberculosis" by combined rifampicin-ethambutol: preliminary results of a controlled survey made in Algeria]

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Ambulatory intermittent rifampicin and ethambutol in the retreatment of pulmonary tuberculosis.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

[Controlled study comparing 3 daily chemotherapy regimens for six months in pulmonary tuberculosis in routine practice in Algiers. Results at 30 months]

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Reappraisal of the activity of morphazinamide against M. tuberculosis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Combined rifampicin-ethambutol therapy of resistent pulmonary tuberculosis. Effectiveness of various rifampicin doses in combination with ethambutol

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence

20 June 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2015-208262

Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2015-208262

A Controlled Trial of 3-Month, 4-Month, and 6-Month Regimens of Chemotherapy for Sputum-smear-negative Pulmonary Tuberculosis: Results at 5 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2015-208262

Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2015-208262

A CONTROLLED COMPARISON OF STREPTOMYCIN PLUS PYRAZINAMIDE AND STREPTOMYCIN PLUS PAS IN THE RETREATMENT OF PATIENTS EXCRETING ISONIAZID-RESISTANT ORGANISMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2015-208262

INFLUENCE OF PRETREATMENT BACTERIAL RESISTANCE TO ISONIAZID, THIACETAZONE OR PAS ON THE RESPONSE TO CHEMOTHERAPY OF AFRICAN PATIENTS WITH PULMONARY TUBERCULOSIS

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036252

Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study

26 November 2018

1 reference

12 December 2020

COMPARATIVE trial of isoniazid in combination with sulphone or PAS in the treatment of acute pulmonary tuberculosis in East Africans; a co-operative investigation in East African hospitals and laboratories with the collaboration of the British Medic

1 reference

12 December 2020

A controlled clinical trial of the role of thiacetazone-containing regimens in the treatment of pulmonary tuberculosis in Singapore: second report

1 reference

12 December 2020

Network meta-analysis for indirect treatment comparisons

1 reference

12 December 2020

[Efficiency of a new standard chemotherapy regimen in the treatment of patients with recurrent pulmonary tuberculosis]

1 reference

12 December 2020

Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment

1 reference

12 December 2020

Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

12 December 2020

A comparative study of daily followed by twice- or once-weekly regimens of ethambutol and rifampicin in the retreatment of patients with pulmonary tuberculosis: second report

1 reference

12 December 2020

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report

1 reference

12 December 2020

Comparative study (in a controlled therapeutic trial) of 3 intermittent regimens, after an initial period of daily administration, in the repeated treatment of pulmonary tuberculosis (results)

1 reference

12 December 2020

Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis--a controlled trial of our regimens

1 reference

12 December 2020

Toxicity of morphazinamide compared with pyrazinamide

1 reference

12 December 2020

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils

1 reference

12 December 2020

Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India

1 reference

12 December 2020

A study of two twice-weekly and a once-weekly continuation regimen of tuberculosis chemotherapy, including a comparison of two durations of treatment 2. Second report: The results at 36 months

1 reference

12 December 2020

A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore

1 reference

12 December 2020

Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study

1 reference

12 December 2020

Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study

1 reference

12 December 2020

Cooperative controlled trial of thiocarlide (DATC), PAS and bedrest alone in short-term single-drug treatment in retreated cavitary pulmonary tuberculosis

1 reference

12 December 2020

A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre

1 reference

12 December 2020

Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month

1 reference

12 December 2020

A comparison of two regimens of streptomycin plus pas in the retreatment of pulmonary tuberculosis†‡

1 reference

12 December 2020

Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

12 December 2020

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study

1 reference

12 December 2020

A controlled comparison of two fully supervised once-weekly regimens in the treatment of newly diagnosed pulmonary tuberculosis

1 reference

12 December 2020

A CONTROLLED TRIAL OF ETHIONAMIDE WITH ISONIAZID IN THE TREATMENT OF PULMONARY TUBERCULOSIS IN HONG KONG

1 reference

12 December 2020

Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. A Kenyan/Zambian/British Medical Research Council Collaborative Study

1 reference

12 December 2020

Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months

1 reference

12 December 2020

Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council

1 reference

12 December 2020

Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa--fifth investigation. A co-operative study in East African hospitals, clinics and laboratories with the collaboration of the East African and Briti

1 reference

12 December 2020

A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigat

1 reference

12 December 2020

Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months

1 reference

12 December 2020

Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

12 December 2020

Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study

1 reference

12 December 2020

A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months

1 reference

12 December 2020

Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis

1 reference

12 December 2020

Daily and intermittent regimens using ethambutol and rifampicin in the treatment of unresponsive cases. (Evaluation after 1 year.) I. Clinical course

1 reference

12 December 2020

Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: The results up to 24 months

1 reference

12 December 2020

[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose]

1 reference

12 December 2020

Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria. Algerian Working Group/British Medical Research Council Cooperative Study

1 reference

12 December 2020

10.1136/THORAXJNL-2015-208262

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298314%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference